Nuzenio

Kymera Therapeutics

Kymera Therapeutics news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 24 latest news signals 14 publisher sources 100/100 entity strength

Latest news

A Quick Look at Today's Ratings for Kymera Therapeutics(KYMR.US), With a Forecast Between $116 to $139 - MoomooMoomoo · Fri, 07 Aug 2026 15:23:15 GMTsymbol__ Stock Quote Price and Forecast - CNNCNN · Fri, 07 Aug 2026 14:17:26 GMTRBC Capital Downgrades Kymera Therapeutics(KYMR.US) to Hold Rating, Raises Target Price to $112 - MoomooMoomoo · Fri, 07 Aug 2026 05:18:39 GMTKYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 18:52:00 GMTKYMR Maintains Overweight by Barclays -- Price Target Raised to $139 - GuruFocusGuruFocus · Thu, 06 Aug 2026 16:37:59 GMTKYMERA THERAPEUTICS, INC. : CITIGROUP RAISES TARGET PRICE TO $135 FROM $120 - BitgetBitget · Thu, 06 Aug 2026 11:13:27 GMTKymera’s KT-621 atopic dermatitis trial closes enrollment six months early - The Clinical Trial VanguardThe Clinical Trial Vanguard · Thu, 06 Aug 2026 06:43:58 GMTKYMR SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocusGuruFocus · Thu, 06 Aug 2026 06:25:39 GMT

Timeline

Fri, 07 Aug 2026 15:23:15 GMTA Quick Look at Today's Ratings for Kymera Therapeutics(KYMR.US), With a Forecast Between $116 to $139 - Moomoo
Fri, 07 Aug 2026 14:17:26 GMTsymbol__ Stock Quote Price and Forecast - CNN
Fri, 07 Aug 2026 05:18:39 GMTRBC Capital Downgrades Kymera Therapeutics(KYMR.US) to Hold Rating, Raises Target Price to $112 - Moomoo
Thu, 06 Aug 2026 18:52:00 GMTKYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments - Yahoo Finance
Thu, 06 Aug 2026 16:37:59 GMTKYMR Maintains Overweight by Barclays -- Price Target Raised to $139 - GuruFocus
Thu, 06 Aug 2026 11:13:27 GMTKYMERA THERAPEUTICS, INC. : CITIGROUP RAISES TARGET PRICE TO $135 FROM $120 - Bitget

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Kymera Therapeutics.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

14 distinct publisher/source names are currently connected to this entity page.